Professor Andrew Gorringe has been involved in vaccine development and evaluation for 40 years. He was apart of a group that developed an acellular pertussis vaccine in the early 1990s. 

He then worked on meningococcal vaccines and identified several novel vaccine antigens. He led the development of an outer membrane vesicle vaccine from discovery to a phase 1 clinial trial. 

More recent research has foccused on immune correlates of protextion and antibody and complement interactions for Bordetella pertussis, Neisseria meningitidis, Group B streptococcus (GBS), Haemophilus and more recently SARS-CoV-2. We are also part of an international consortium developing standard immunoassays for GBS.